Insights

Pedro Barata, MD, MSc, and Benjamin Garmezy, MD, discuss the evolving treatment landscape for advanced renal cell carcinoma.

Expert perspectives on the evolving treatment paradigm of HER2-expressing breast cancer and how learnings from recent clinical trials are impacting real-world practices.

Komal Jhaveri, MD, FACP, and Paolo Tarantino, MD, discuss updates in the treatment of metastatic breast cancer (mBC) from SABCS 2022 and other recent meetings, and how to best incorporate recent data into clinical practice.

Expert oncologists discuss the hormone receptor–positive (HR+) breast cancer treatment landscape and their suggested approaches to treating patients in both the early and metastatic disease settings.

An expert panel discusses recent advances in the treatment of Stage I-III NSCLC and their impact on clinical practice.

Expert oncologist Martin Dietrich, MD, PhD, shares his excitement for an upcoming program wherein he and Meghan Mooradian, MD, highlight the evolving role of immunotherapy and biomarker-driven therapy in non-small cell lung cancer.

Expert perspectives on the prevention and treatment of tumor lysis syndrome (TLS) in patients on therapy for cancer.

Shaji Kumar, MD, and Krina Patel, MD, discuss key updates in the diagnosis and treatment of multiple myeloma. Jenny Ahlstrom, a patient, and Bonnie Falbo, a caregiver and patient advocate, share their personal journeys with multiple myeloma.

Expert oncologists work together to review the current treatment paradigm for metastatic castration-resistant prostate cancer in the context of clinical trials and real-world experience.

Expert perspectives on the advent of KRAS G12C mutations in non–small cell lung cancer, with a focus on the development of targeted therapies in this setting.

Brian Hill, MD, PhD and Lori Leslie, MD, discuss their respective treatment approaches to relapsed/refractory follicular lymphoma (R/R FL), sharing patient cases, reviewing treatment options for patients with the disease, and providing clinical advice for community-based oncologists.

Tanios S. Bekaii-Saab, MD, analyzes the common adverse events (AEs) associated with tyrosine kinase inhibitors (TKIs) across solid tumors, with a special focus on hepatotoxicity and the clinical implications of this AE for future clinical studies of TKIs in combination with immune checkpoint inhibitors.

Joseph Mikhael, MD, and Craig Cole, MD, discuss the substantial disparities in incidence and survival rates between patient populations with multiple myeloma, especially between Black and white Americans.

Expert oncologists center discussion on a clinical scenario to highlight optimal treatment strategies in metastatic endometrial cancer (mEC).

Expert oncologists center discussion on a clinical scenario to highlight optimal treatment strategies in metastatic triple-negative breast cancer.

Brea Lipe, MD, and Peter Forsberg, MD, discuss updates in the treatment of R/R multiple myeloma, and present two hypothetical patient profiles to show how recent data can be incorporated into clinical practice.

Dr Shaji Kumar and Dr Jonathan Kaufman discuss the evolving role of biomarkers in multiple myeloma.

Mark Pegram, MD, and Lee Schwartzberg, MD, FACP, have a discussion on the management of early-stage hormone-receptor-positive breast cancer and the tools available to help inform treatment decisions.